Affiliation: Montefiore Medical Center
- Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinomaMinaxi Jhawer
Montefiore Medical Center, NY, USA
Invest New Drugs 25:85-94. 2007..To evaluate the tolerability and efficacy of nolatrexed in patients with advanced hepatocellular carcinoma...
- Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinomaManish A Shah
Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and the Weill School of Medicine, Cornell University, New York, NY, USA
J Clin Oncol 29:868-74. 2011..To evaluate the safety and efficacy of a modified administration schedule of docetaxel, cisplatin, and fluorouracil (mDCF) with bevacizumab in patients with advanced gastroesophageal malignancies...
- PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximabMinaxi Jhawer
Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY 10467, USA
Cancer Res 68:1953-61. 2008..A priori screening of colon tumors for PTEN expression status and PIK3CA and Ras/BRAF mutation status could help stratify patients likely to benefit from this therapy...
- Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignanciesSanjay Goel
Department of Hematology Oncology, Montefiore Medical Center Albert Einstein College of Medicine and Albert Einstein Comprehensive Cancer Center Bronx, NY 10461, USA
Am J Clin Oncol 25:528-34. 2002..The combination of irinotecan 275 mg/m(2) and capecitabine 2,300 mg/d represents a safe, favorable, and convenient outpatient regimen warranting further phase II evaluation...